IDH2 and acute myeloid leukemia: In subgroup analyses of patients with somatic mutations in TP53, IDH, FMS-like tyrosine kinase 3 (FLT3) or Nucleophosmin-1 (NPM1), combination venetoclax and LDAC resulted in a CR rate of 57% in patients with IDH1 mutated AML, consistent with data seen in other studies showing increased benefit of venetoclax in IDH mutant disease.